Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ceftriaxone
Drug ID BADD_D00405
Description Ceftriaxone is a broad-spectrum third-generation cephalosporin antibiotic.[A215582] It has a very long half-life compared to other cephalosporins and is high penetrable into the meninges[A215582], eyes[A215647], and inner ear[A215627]. Ceftriaxone has broader and stronger gram-negative coverage then first or second-generation cephalosporins, but worse activity against methicillin-susceptible S.aureus. Ceftriaxone is a commonly used antimicrobial due to its good activity against multi-drug resistant Enterobacteriaceae, its relatively safe adverse effect profile, and its long half-life which allows for the convenience of daily or twice-daily dosing.[A215582]
Indications and Usage Ceftriaxone is used for the treatment of the infections (respiratory, skin, soft tissue, UTI, ENT) caused by susceptible organisms.[L15082] Organisms that are generally susceptible to ceftriaxone include S. pneumoniae, S. pyogenes (group A beta-hemolytic streptococci), coagulase-negative staphylococci, Some Enterobacter spp, H. influenzae, N. gonorrhoeae, P. mirabilis, E. coli, Klebsiella spp, M. catarrhalis, B. burgdorferi, and some oral anaerobes.[A215582]
Marketing Status approved
ATC Code J01DD04
DrugBank ID DB01212
KEGG ID D07659
MeSH ID D002443
PubChem ID 5479530
TTD Drug ID D07ACT
NDC Product Code 72572-061; 25021-105; 25021-107; 44567-700; 63323-346; 0143-9859; 66794-213; 71205-593; 72572-062; 66794-215; 70594-098; 44567-701; 66794-211; 70518-3355; 25021-106; 0143-9856; 44567-702; 66794-214; 70594-094; 70594-097; 0264-3155; 66794-212; 44567-703; 0264-3153; 70594-095; 70594-096; 0143-9678; 0143-9857; 0143-9858
UNII 75J73V1629
Synonyms Ceftriaxone | Ceftriaxon | Cefatriaxone | Ceftriaxone, Disodium Salt, Hemiheptahydrate | Ceftrex | Ceftriaxon Curamed | Ceftriaxon Hexal | Ceftriaxona Andreu | Ceftriaxona LDP Torlan | Ceftriaxone Irex | Ceftriaxone Sodium | Ceftriaxone Sodium, Anhydrous | Anhydrous Ceftriaxone Sodium | Lendacin | Longacef | Longaceph | Ro13-9904 | Ro13 9904 | Ro139904 | Ro-13-9904 | Ro 13-9904 | Ro 13 9904 | Ro 139904 | Rocephin | Rocefalin | Rocephine | Rocefin | Tacex | Terbac | Ceftriaxone, Disodium Salt | Benaxona | Cefaxona
Chemical Information
Molecular Formula C18H18N8O7S3
CAS Registry Number 73384-59-5
SMILES CN1C(=NC(=O)C(=O)N1)SCC2=C(N3C(C(C3=O)NC(=O)C(=NOC)C4=CSC(=N4)N)SC2)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Toxic encephalopathy17.13.01.004; 12.03.01.0270.040109%Not Available
Toxic epidermal necrolysis23.03.01.008; 12.03.01.015; 11.07.01.006; 10.01.01.0060.049022%
Tremor17.01.06.002--
Tricuspid valve incompetence02.07.05.0010.008913%Not Available
Type I hypersensitivity10.01.03.0060.004457%Not Available
Unresponsive to stimuli17.02.05.0310.044565%Not Available
Ureteric obstruction20.06.01.0050.015598%Not Available
Urinary incontinence20.02.02.010; 17.05.01.0080.008913%
Urine glucose false positive13.02.02.006--Not Available
Urticaria23.04.02.001; 10.01.06.0010.386383%
Uterine atony18.07.02.012; 21.07.03.0010.004457%Not Available
Vaginal infection21.14.02.002; 11.01.10.002--
Vena cava thrombosis24.01.10.0010.008913%Not Available
Ventricular fibrillation02.03.04.0080.031196%
Ventricular tachycardia02.03.04.0100.008913%
Vomiting07.01.07.0030.219262%
Wheezing22.03.01.0090.049913%
Mental status changes19.07.01.0010.029859%Not Available
Tubulointerstitial nephritis20.05.02.0020.054370%Not Available
Cardiotoxicity02.11.01.009; 12.03.01.0070.006685%Not Available
Hydrothorax22.05.02.0040.004457%Not Available
Acute generalised exanthematous pustulosis11.07.01.018; 10.01.01.034; 23.03.10.002; 12.03.01.0050.100272%Not Available
Localised oedema14.05.06.009; 08.01.07.011; 02.05.04.0060.011141%
Brain oedema17.07.02.003; 12.01.10.0100.006685%
Brain death17.02.03.003; 08.04.01.0040.008913%Not Available
General physical health deterioration08.01.03.0180.024511%Not Available
Urethral haemorrhage24.07.03.006; 20.07.01.0030.004457%Not Available
Shock haemorrhagic24.06.02.014; 14.05.05.0030.006685%Not Available
Dysstasia15.03.05.011; 08.01.03.089; 17.02.02.0120.004457%Not Available
Cardiopulmonary failure22.02.06.004; 02.05.01.0040.006685%Not Available
The 12th Page    First    Pre   12 13 14 15 16    Next   Last    Total 16 Pages